RBC Capital lowered the firm’s price target on Inovio (INO) to $5 from $6 and keeps a Sector Perform rating on the shares. The company ...

Inovio Pharmaceuticals (NASDAQ:INO – Free Report) had its target price lowered by Royal Bank of Canada from $6.00 to $5.00 in a research report sent to investors on Wednesday,Benzinga reports. The ...

Inovio plans to begin submitting the BLA for INO-3107 in mid-2025, with a goal of achieving FDA acceptance for filing by year-end 2025. Priority review will also be requested.

Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.

In a report released yesterday, Gregory Renza from RBC Capital maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report), with ...

Inovio Pharmaceuticals Inc. closed 86.10% short of its 52-week high of $14.75, which the company achieved on April 1st.

Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results conference call. At this time, all lines are in listen-only mode.

Oasis Management Company Ltd. ("Oasis") is the manager to funds that beneficially own approximately 11.5% of Japan ink and chemical products manufacturer DIC Corporation (4631 JT) ("DIC" or the ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ...

Stay updated on market trends for INO. Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed ...

Legacy EV is the market leader in EV adoption, providing fully integrated EV systems, certified technician training, and EV design consultation. By offering innovative education programs like the EV ...